AZN - AstraZeneca to expand rare disease pipeline with $1.05B Amolyt Pharma acquisition
2024-03-14 06:00:46 ET
In a bid to strengthen its rare disease portfolio, AstraZeneca ( NASDAQ: AZN ) has agreed to acquire biotechnology company Amolyt Pharma for $1.05B, on a cash and debt free basis....
AstraZeneca to expand rare disease pipeline with $1.05B Amolyt Pharma acquisition